“My creatinine is fine” can be misleading: KDIGO 2024 pushes cystatin C for more accurate kidney staging

Medical review: Reviewed by Gary A. Webb MD MS FAAFP, Medical Director at HealthE1 Mobile Medical Services on February 14, 2026. Fact-checked against government and academic sources; see in-text citations. This page follows our Medical Review & Sourcing Policy and undergoes updates at least every six months.

Here’s what you’ll learn when you read this article:

• Why a “normal” creatinine result can miss early or moderate kidney disease in real-world patients
• How cystatin C and combined eGFR improve kidney staging accuracy in KDIGO 2024 guidance
• When adding cystatin C can change monitoring, medication safety, and clinical decisions

People often hear a reassuring phrase after routine blood work: “Your creatinine looks fine.” For many patients, that single sentence ends the conversation about kidney health. Current kidney guidelines make it clear that this reassurance can be incomplete, and in some cases misleading, especially when creatinine is used alone to estimate kidney function.

In 2024, the KDIGO 2024 CKD guideline updated its chronic kidney disease (CKD) recommendations with a stronger emphasis on cystatin C. The recommendation reflects years of evidence showing that creatinine-based estimates can miss early or moderate kidney impairment in real-world patients. Understanding why this matters helps people make sense of confusing lab results and ask better questions during medical visits.

Why kidney function is estimated, not directly measured

Kidneys filter waste products from the blood, a process known as glomerular filtration. Measuring that filtration directly requires specialized tests that are time-consuming, costly, and impractical for routine care. Clinical medicine instead relies on estimated glomerular filtration rate, or eGFR, calculated from substances found in the blood.

Creatinine has served as the traditional marker for decades. The body produces creatinine from muscle metabolism, and healthy kidneys clear it efficiently. When kidney filtration declines, creatinine levels generally rise, allowing clinicians to estimate kidney function with mathematical equations.

That approach works well for many people, yet it assumes that creatinine production remains fairly constant. Real patients rarely fit that assumption perfectly, which explains why KDIGO now emphasizes supplementing creatinine with another marker when accuracy matters.

How creatinine can appear “normal” when kidney function is not

Creatinine reflects muscle mass as much as kidney filtration. People with lower muscle mass generate less creatinine each day, which can keep blood levels low even when kidney clearance has declined. Older adults commonly experience gradual muscle loss, and frailty can accentuate this effect.

Athletes face a different issue. Intense training, high-protein diets, and creatine supplementation can raise creatinine without signaling kidney damage. Heat exposure and dehydration, common in active lifestyles or warm climates, further concentrate creatinine in the blood and create short-term spikes that do not reflect true kidney injury.

Body composition changes also matter. Individuals with amputations, spinal cord injuries, or muscle-wasting illnesses may show deceptively reassuring creatinine values. In each scenario, creatinine’s dependence on muscle production weakens its reliability as a standalone kidney marker.

The difference between “in range” and “accurate”

Laboratory reference ranges create another layer of confusion. A creatinine value can fall within the lab’s normal range while still representing a meaningful decline from a person’s prior baseline. Kidney disease often progresses silently, and small changes over time can matter more than a single snapshot.

Trend analysis helps, yet trends themselves become hard to interpret when non-kidney factors influence creatinine. A patient who exercises intensely before one test and rests before another may show fluctuation that masks real changes in filtration. This uncertainty prompted guideline committees to look for ways to reduce noise in kidney estimates.

What cystatin C adds, in plain language

Cystatin C is a small protein produced by nearly all nucleated cells in the body at a relatively constant rate. Kidneys freely filter it from the blood, and it does not depend on muscle mass for its production. That biological difference makes cystatin C less sensitive to body size, muscle loss, or high physical activity.

KDIGO’s 2024 guideline states that when cystatin C is available, clinicians should estimate GFR using both creatinine and cystatin C together. The combined equation improves accuracy across diverse populations, particularly when creatinine alone may misclassify kidney stage.

Using two markers reduces the chance that bias from one overwhelms the estimate. If creatinine underestimates risk because of low muscle mass, cystatin C helps correct that signal. When creatinine rises from exercise or dehydration, cystatin C can show whether filtration truly changed.

Why guideline writers strengthened the recommendation

The push toward combined testing did not arise from theory alone. Large cohort research shows that creatinine-based and cystatin C–based estimates can diverge in ways that correlate with meaningful differences in long-term risk. A patient-facing explanation of how differences between kidney function tests can predict health risks appears in NIH Research Matters: difference in kidney function tests predicts health risks. That evidence supports KDIGO’s stronger emphasis on combined estimates when availability and decision stakes make added precision worthwhile.

When cystatin C–based eGFR was substantially lower than creatinine-based eGFR, patients faced higher risks of death and cardiovascular complications over time. The gap itself carried prognostic information, suggesting that discordance often signals underlying vulnerability rather than random variation.

Guideline committees weighed this evidence alongside practical considerations. Cystatin C testing remains less available than creatinine in some settings, yet its value in refining staging and guiding decisions justified a stronger recommendation whenever laboratories can provide it.

Understanding kidney staging beyond a single number

Kidney disease staging relies on more than eGFR alone. Urine albumin levels indicate how much protein leaks through the kidneys, adding essential context to filtration estimates. Someone with mildly reduced eGFR but high urine albumin may face greater risk than another person with a lower eGFR and no albumin leakage.

KDIGO’s framework emphasizes combining filtration category and albumin category to guide monitoring frequency and referral decisions. Accurate eGFR matters because it anchors this entire risk grid. Misclassification at the eGFR level can ripple through care plans, follow-up schedules, and patient counseling.

When combined creatinine and cystatin C estimates matter most

Not every lab report requires cystatin C. KDIGO and the KDOQI US commentary highlight situations where greater precision affects real decisions. Borderline eGFR results that straddle two stages often change monitoring intensity or prompt referral discussions.

Medication dosing presents another common scenario. Many drugs clear through the kidneys, and dosing errors increase when kidney function is misestimated. Imaging studies using contrast agents also depend on accurate kidney assessment to balance diagnostic benefit against risk.

Patients whose creatinine values fluctuate widely with hydration, illness, or activity often benefit from combined estimates. In these cases, cystatin C can stabilize interpretation and prevent unnecessary alarm or false reassurance.

This chart summarizes common real-life situations where creatinine-based eGFR can mislead, and where KDIGO 2024 supports adding cystatin C (when available) to improve kidney staging accuracy. Use it as a discussion guide to decide whether combined eGFR could change monitoring, staging, or medication decisions.

Situation	Why creatinine alone can mislead	What cystatin C / combined eGFR can improve	Practical question to ask your clinician
Older adults, frailty, or noticeably low muscle mass	Lower muscle production can keep creatinine “normal,” even when filtration declines.	Combined eGFR (creatinine + cystatin C) can reduce misclassification of CKD stage when creatinine underestimates risk.	“Would combined creatinine + cystatin C eGFR change my CKD stage or monitoring plan?”
Extreme sport / intense training / body-building patterns	Creatinine can shift with muscle turnover and training load, creating misleading eGFR changes.	Cystatin C helps interpret kidney function when muscle-related creatinine variation adds noise.	“Could cystatin C help confirm whether these eGFR swings reflect kidney function or training effects?”
Recent dehydration or heat exposure	Dehydration can raise creatinine temporarily, lowering eGFR without true, persistent loss of filtration.	A second marker can help clarify whether the change matches a true filtration shift or a short-term distortion.	“Should we repeat testing under stable hydration, or add cystatin C now for clearer staging?”
Creatine supplements or high-protein diet patterns	Diet and creatine supplementation can alter creatinine and complicate interpretation of creatinine-based eGFR.	Combined eGFR reduces reliance on creatinine alone when non-kidney influences are likely.	“Given my supplements/diet, would cystatin C help avoid a false alarm or false reassurance?”
Amputation (for example above-knee) or spinal cord injury	Lower muscle mass can lower creatinine generation, making creatinine-based eGFR look better than true filtration.	Cystatin C (and especially combined eGFR) can improve staging accuracy when creatinine becomes unreliable due to altered muscle mass.	“Is creatinine-based eGFR likely to underestimate CKD in my case, and should we add cystatin C?”
Borderline eGFR results where stage affects the care plan	Small errors in creatinine-based eGFR can push a patient into the wrong GFR category.	KDIGO 2024 supports combined eGFR for more accurate diagnosis and staging when cystatin C is available.	“If we add cystatin C, could my GFR category or follow-up schedule change?”
High-stakes medication decisions (kidney-cleared drugs)	Creatinine-based estimates can be less accurate in certain clinical situations, which can affect dosing decisions.	KDOQI notes combined eGFR can improve accuracy when eGFR affects clinical decision-making, and it highlights select situations where measured GFR may be needed.	“Does dosing depend enough on GFR accuracy that we should use eGFRcr-cys, or consider measured GFR?”
Large difference between creatinine-eGFR and cystatin C–eGFR (discordance)	Discordance can signal that non-kidney factors influence one marker, making “creatinine is fine” an incomplete risk picture.	Population-level evidence links large discordance (especially lower cystatin C eGFR) with higher risk, and combined eGFR can better align staging with risk.	“How should we interpret the difference, and does it change my monitoring or risk-reduction plan?”

When cystatin C also has limits

No blood marker perfectly reflects kidney filtration in every circumstance. Certain inflammatory states, thyroid disorders, or high-dose steroid use can influence cystatin C levels. Combined equations mitigate many biases, yet clinicians sometimes need measured GFR for critical decisions, such as chemotherapy dosing or transplant evaluation.

Recognizing limits helps patients understand why additional testing may be recommended. The goal remains matching the accuracy of assessment to the importance of the decision at hand.

Making sense of discordant results

Patients sometimes see two different estimates, such as eGFR from creatinine and eGFR from cystatin C. Each estimate uses a different blood marker, so each one can “pick up” different non-kidney influences in real life. KDIGO explains this shift toward more accurate staging and risk framing, including greater emphasis on combined equations, in its KDIGO 2024 CKD Guideline Executive Summary (PDF). A clinician usually interprets discordance by pairing the numbers with urine findings, history, and the reason testing happened in the first place.

Large gaps between creatinine-based and cystatin C–based estimates matter because studies link that mismatch with higher long-term risk in some populations. The key point involves risk stratification, not instant conclusions about irreversible decline. A helpful public-facing summary of this concept appears in NIH Research Matters: difference in kidney function tests predicts health risks. When clinicians see a meaningful mismatch, they often respond with closer follow-up and a tighter focus on modifiable risk factors.

For patients, the most useful next step usually involves clarifying what the lab reported and why the estimate might differ across markers. A grounded discussion often includes which equation the lab used, whether urine albumin testing adds context, and whether a combined estimate could change staging or decisions. The National Kidney Foundation: FAQs about GFR estimates (PDF) offers a practical overview of how clinicians think about estimates and why they can vary. That approach supports planning without turning one isolated number into a verdict.

Real-world preparation for kidney labs

Everyday factors can distort kidney markers temporarily. Heavy exercise shortly before blood work raises creatinine independent of filtration. Dehydration from illness, travel, or heat exposure concentrates blood values and exaggerates impairment.

Patients benefit from consistency. Scheduling labs when feeling well hydrated and avoiding intense workouts beforehand produces results closer to baseline. Supplements, especially creatine, deserve disclosure because they influence interpretation.

Medication lists also matter. Clinicians rely on accurate information to decide whether observed changes reflect drug effects or kidney decline. Clear communication prevents unnecessary testing and confusion.

The role of at-home blood draws in monitoring

Frequent monitoring challenges many people, particularly older adults or those with mobility limitations. Missed follow-ups can delay recognition of trends that matter more than isolated results. Services that bring phlebotomy to the home help reduce these gaps when ordered appropriately by clinicians.

HealthE1 Mobile Medical Services in Naples, Florida emphasizes patient education during this process, helping individuals understand what tests are ordered and why timing matters. Keeping patients informed supports more reliable monitoring rather than passive lab collection.

At-home testing does not replace medical interpretation. Results still require clinical context, review of symptoms, and integration with urine findings and blood pressure trends.

Talking with clinicians about kidney accuracy

Effective conversations start with clarity. Patients can ask which eGFR equation their lab uses and whether cystatin C is available locally. Discussing urine albumin testing alongside blood results helps frame risk more completely.

Questions about trends deserve attention. Understanding whether a change represents measurement noise or real decline shapes next steps. Shared decision-making becomes easier when patients grasp why additional testing may add value.

HealthE1 Mobile Medical Services in Naples, Florida also encourages patients to keep personal records of lab dates and circumstances, supporting more meaningful discussions with their healthcare teams.

Practical scenarios patients often face

A retired runner notices rising creatinine after summer training sessions. Combined testing shows stable filtration, easing concern and avoiding unnecessary referrals. An older adult with weight loss sees creatinine remain “normal,” yet cystatin C reveals moderate CKD, prompting earlier blood pressure optimization.

Another patient experiences wide creatinine swings during travel. Adding cystatin C clarifies baseline kidney function and guides safer medication dosing. These scenarios illustrate how combined markers align lab data with lived experience.

3 Practical Tips

• Keep a brief note for each kidney lab with hydration status, recent exercise, illness, and supplements to add context to results.
• Ask whether urine albumin testing accompanies eGFR when kidney staging or risk is discussed.
• If creatinine seems inconsistent with symptoms or body composition, ask whether adding cystatin C would change management.

Frequently Asked Questions

Do I need cystatin C if my creatinine is normal?

Normal-range creatinine does not guarantee accurate kidney staging, particularly in people with low or unusual muscle mass. Cystatin C helps confirm filtration when creatinine may underestimate risk. Clinicians often consider it when results influence monitoring or treatment decisions.

Why did my eGFR change after exercise or dehydration?

Creatinine rises with muscle breakdown and concentrates during dehydration, altering eGFR without true kidney injury. These shifts usually normalize with rest and hydration. Repeating labs under stable conditions clarifies baseline function.

If creatinine and cystatin C estimates differ, which one is right?

Neither marker acts as an absolute truth in isolation. Clinicians interpret the pattern using combined equations, urine findings, and clinical context. Large differences often prompt closer follow-up rather than immediate conclusions.

How often should kidney function be checked?

Monitoring frequency depends on kidney stage, urine albumin level, blood pressure, diabetes status, and recent changes. Stable early-stage disease may require annual testing, while higher-risk patterns need more frequent review. Decisions remain individualized and clinician-guided.

Understanding why creatinine alone can mislead helps patients frame better questions about accuracy, not just “normal ranges.” KDIGO summarizes the guideline’s direction toward more accurate staging in its KDIGO 2024 CKD Guideline Executive Summary (PDF), while a plain-language look at why test differences can matter appears in NIH Research Matters. For readers who want a practical primer on estimated GFR, the National Kidney Foundation’s GFR FAQs (PDF) provides helpful context, and MedlinePlus offers a straightforward overview of the creatinine test. These references support the same core idea: accuracy improves when lab interpretation matches the person behind the number.